Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-16T06:21:15.187Z Has data issue: false hasContentIssue false
  • English
  • Français

Selective Benefit of Donepezil on Oral Naming in Alzheimer's Disease in Men Compared to Women

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Communique
Information
CNS Spectrums , Volume 14 , Issue 4 , April 2009 , pp. 175 - 177
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Rogers, SL, Farlow, MR, Doody, RS, et al.A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136–145.CrossRefGoogle ScholarPubMed
2.Barrett, AM, Eslinger, PJ, Ballentine, NH, et al.Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology. 2005;64:693–699.CrossRefGoogle ScholarPubMed
3.Folstein, MF, Folstein, SE, McHugh, PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.CrossRefGoogle Scholar
4.Kaplan, E, Goodglass, H, Weintraub, S. Boston Naming Test. Media, Penn: Williams & Wilkins; 1983.Google Scholar
5.Brandt, J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125–142.CrossRefGoogle Scholar
6.Takeda, A, Loveman, A, Clegg, J, et al.A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21:17–28.CrossRefGoogle ScholarPubMed
7.Haywood, WM, Mukaetova-Ladinska, EB. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's Disease. Am J Geriatr Pharmacother. 2006;4:273–286.CrossRefGoogle ScholarPubMed
8.MacGowan, SH, Wilcock, GK, Scott, M. Effect of sex and apolipoprotein E genotype on response to anthicholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry. 1998;13:625–630.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
9.King, KA, Hough, MS, Walker, MM, et al.Mild traumatic brain injury: Effects on naming in word retrieval and discourse. Brain Inj. 2006;20:725–732.CrossRefGoogle ScholarPubMed
10.Klein, RB, Martin, LA. Can drug therapies improve language functions of individuals with aphasia? A review of the evidence. Semin Speech Lang. 2004;25:193–220.CrossRefGoogle ScholarPubMed